Prescribers Should Restrict the Use of Non-FDA-Approved Compounded Bioidentical Hormones, Except for Specific Medical Circumstances
The use of compounded bioidentical hormone therapies (cBHTs) — an increasingly popular approach to relieve symptoms of menopause and male hypogonadism — should be limited to the small number of patients who cannot benefit from an FDA-approved hormone therapy product, says a new report from the National Academies of Sciences, Engineering, and Medicine.
More from Science & TechnologyMore posts in Science & Technology »
- Stranded Killer Whale Survives With Help of Good Samaritans
- Anyway I can turn an old phone to a Smart IR blaster controllable by Google Home?
- Looking for low voltage Alexa compatible iot module.
- The ‘Hydrogen Olympics’ Lit a Torch for the Clean Fuel’s Future
- Driving Motors in Battery-powered IoT Systems